Novo Nordisk A/S (NVO) shares dropped 9.18% to $46.85 after its Phase 3 ZEUS trial failed to demonstrate a reduction in major cardiovascular events, raising concerns about the clinical and commercial prospects of its investigational anti-inflammatory therapy ziltivekimab.

The setback comes despite the drug showing clear biological activity against markers of inflammation associated with cardiovascular disease and kidney damage. Novo Nordisk confirmed that the ZEUS outcome will not affect its adjusted operating profit outlook for the full 2026 financial reporting year.

Ziltivekimab, an anti-IL-6 monoclonal antibody, entered Novo Nordisk's pipeline through the company's acquisition of Corvidia Therapeutics in 2020 for approximately $725 million. The drug represents the Danish drugmaker's effort to expand its cardiovascular portfolio beyond its established diabetes and obesity franchise, which is anchored by semaglutide-based products Ozempic and Wegovy.

ZEUS Trial Misses Primary Cardiovascular Endpoint

Novo Nordisk evaluated ziltivekimab in more than 6,300 patients with cardiovascular disease, kidney disease, and persistent systemic inflammation. The Phase 3 study compared a monthly 15-milligram dose of ziltivekimab against a placebo under controlled, double-blind conditions.

The combined primary efficacy endpoint measured cardiovascular death, non-fatal heart attacks, and non-fatal strokes. Ziltivekimab successfully reduced free interleukin-6 and high-sensitivity C-reactive protein, confirming strong target engagement across the treated patient group. However, those biological improvements did not translate into a reduction in major adverse cardiovascular events compared with placebo over the extended trial period.

The disconnect between biomarker reduction and clinical outcome adds to a challenging track record for anti-inflammatory therapies in cardiovascular medicine. Novartis's CANTOS trial, which tested the IL-1β inhibitor canakinumab, demonstrated a statistically significant but modest reduction in cardiovascular events in 2017, yet the company ultimately discontinued development of the drug for cardiovascular indications.

The study reported a hazard ratio of 0.99, with a 95% confidence interval ranging from 0.88 to 1.11.

Overall adverse events and serious adverse events remained broadly comparable between the ziltivekimab and placebo arms. However, serious infections occurred more frequently among patients receiving the drug, consistent with the known effects of IL-6 pathway inhibition. Novo Nordisk found no meaningful difference in overall mortality between the two study groups during follow-up.

Broader Cardiovascular Program Continues

Despite the disappointing ZEUS result, Novo Nordisk will proceed with two other cardiovascular outcome trials involving ziltivekimab. The HERMES study is testing the drug in patients living with heart failure and ongoing cardiovascular risk. The ARTEMIS trial is evaluating ziltivekimab in patients recovering from an acute heart attack who face further complications.

Both studies are expected to report headline results during the first half of 2027, according to the company's current development timeline. Their trial designs target different cardiovascular settings, which could produce outcomes that differ materially from those observed in the ZEUS population. Novo Nordisk therefore retains important clinical readouts before determining the experimental medicine's longer-term development future.

Financial Impact

The ZEUS result will trigger a non-cash impairment charge during the third quarter of the 2026 financial year. Novo Nordisk stated that this charge will not alter its previously issued adjusted operating profit guidance for 2026.

The stock decline reflects investor concern over pipeline value following the trial's failure to meet its central cardiovascular objective.